Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), and hyoscine butylbromide, an antispasmodic agent.
## Primary Indications
* Symptomatic relief of spasmodic abdominal pain, particularly associated with menstruation (dysmenorrhea).
## Adult Dosing
* **Mefenamic acid:** 500 mg orally every 8 hours as needed. Maximum dose: 1500 mg per day.
* **Hyoscine butylbromide:** 10 mg orally every 8 hours as needed. Maximum dose: 30 mg per day.
* *Note: Dosing may vary based on local guidelines and patient response.*
## Pediatric Dosing
* Information regarding pediatric dosing for Meftal spas is not readily available. Mefenamic acid is generally not recommended for children under 14 years of age due to lack of established safety and efficacy data. Hyoscine butylbromide pediatric dosing varies and should be determined by a healthcare professional.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is renally excreted and can cause renal damage. Dose reduction may be necessary.
* **Hepatic Impairment:** Use with caution. Mefenamic acid can exacerbate hepatic disease.
## Contraindications
* Hypersensitivity to mefenamic acid, hyoscine butylbromide, or other NSAIDs.
* History of bronchospasm, asthma, or allergic rhinitis precipitated by aspirin or other NSAIDs.
* Active gastrointestinal bleeding, ulceration, or perforation.
* Severe renal or hepatic impairment.
* Myasthenia gravis.
* Tachyarrhythmias.
* Obstructive uropathy or obstructive gastrointestinal conditions.
* Glaucoma (narrow-angle).
* Prostatic hypertrophy with urinary retention.
* Third trimester of pregnancy.
## Adverse Effects
* **Mefenamic Acid:** Gastrointestinal upset (nausea, vomiting, diarrhea, abdominal pain), dyspepsia, constipation, dizziness, headache, drowsiness, rash, fluid retention, hypertension, renal toxicity, increased risk of cardiovascular events.
* **Hyoscine Butylbromide:** Dry mouth, blurred vision, constipation, urinary retention, tachycardia, drowsiness, dizziness.
## Key Drug Interactions
* **Mefenamic Acid:**
* Anticoagulants (e.g., warfarin): Increased risk of bleeding.
* Corticosteroids: Increased risk of gastrointestinal ulceration and bleeding.
* SSRIs/SNRIs: Increased risk of gastrointestinal bleeding.
* Lithium: Increased lithium levels.
* Methotrexate: Increased methotrexate toxicity.
* Other NSAIDs/Aspirin: Increased risk of adverse effects.
* **Hyoscine Butylbromide:**
* Anticholinergic agents: Potentiated anticholinergic effects.
* Opioid analgesics: May increase the risk of severe constipation and ileus.
* Dopamine antagonists (e.g., metoclopramide): May reduce the efficacy of both agents.
## Monitoring
* Monitor for signs and symptoms of gastrointestinal bleeding (e.g., melena, hematemesis).
* Monitor renal function, especially in patients with pre-existing renal disease or those on long-term therapy.
* Monitor for signs of cardiovascular events.
* Monitor for adverse effects related to anticholinergic activity (dry mouth, blurred vision, urinary retention).
## Clinical Pearls
* This combination is primarily used for acute, spasmodic pain, especially dysmenorrhea.
* Mefenamic acid should be taken with food or milk to minimize gastrointestinal upset.
* Due to the risk of anticholinergic side effects, caution is advised in the elderly and in patients with certain medical conditions (e.g., glaucoma, prostatic hypertrophy).
* Long-term use of mefenamic acid is not recommended due to potential for gastrointestinal, renal, and cardiovascular toxicity.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the official prescribing information and relevant guidelines for complete and up-to-date drug information before making clinical decisions.
